TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., May 11, 2023 -- TCR2 Therapeutics Inc. , a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors,... | May 11, 2023

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Kathy Vincent ,Garry Menzel ,Eric Sullivan ,Therapeutics Inc ,Company Tru ,Nasdaq ,American Association For Cancer Research ,Exchange Commission ,Innisfree Ma Incorporated ,Chief Executive Officer ,Adaptimmune Therapeutics ,American Association ,Cancer Research ,Restructuring Expenses ,Investigational New Drug ,Private Securities Litigation Reform Act ,Merger Agreement ,American Depositary Shares ,Annual Report ,Quarterly Report ,Months Ended March ,Tcr2 Therapeutics Inc Stock Exchange ,News ,Information ,Press Release ,Bay ,023 ,Ecr2 ,Herapeutics ,Fell ,Therapy ,Company ,Ith ,Pipeline ,F ,Novel , ,Therapies ,Or ,Patients ,Suffering ,Rom ,Olid Tcrr Us87808k1060 ,